Guru Fundamental Report for UNH

Validea's Martin Zweig Growth Investor model assigns UnitedHealth Group (UNH) a 69% rating, falling below the 80% threshold typically indicating strategic interest. While the large-cap health insurer passes current quarter earnings and valuation criteria, it notably fails on key growth metrics including sales growth rate, earnings growth rate over several quarters, and long-term EPS growth, suggesting a lack of consistent, sustained growth despite strong recent performance.

Analysis

UnitedHealth Group (UNH) receives a 69% rating from Validea's Martin Zweig Growth Investor model, a score that falls below the 80% threshold typically indicating strategic interest. The analysis reveals a notable divergence between the company's short-term performance and its long-term growth consistency. UNH passes on several key criteria, including its P/E ratio, positive current quarter earnings, and favorable insider transactions. Furthermore, its current quarter EPS growth has accelerated, surpassing both the prior three quarters and its historical growth rate. However, the model highlights significant weaknesses by flagging failures in crucial long-term metrics such as the sales growth rate, earnings growth over the past several quarters, earnings persistence, and long-term EPS growth. This suggests that while UNH is demonstrating strong immediate-term profitability and a reasonable valuation, it currently lacks the sustained, accelerating top-line and bottom-line momentum that this specific growth-oriented strategy requires.

Key Decisions for Investors

• Growth-focused investors should be cautious, as the failure on key metrics like sales growth rate and earnings persistence suggests UNH may not currently qualify as a high-momentum compounder despite strong recent earnings.
• Investors should closely monitor upcoming quarterly reports for an improvement in the sales growth rate and multi-quarter earnings trends to determine if the recent strength is sustainable or merely a short-term inflection.
• For those with a 'Growth at a Reasonable Price' (GARP) perspective, the passing P/E ratio and strong current earnings present a point of interest, but this should be weighed against the flagged risks of decelerating long-term growth momentum.